5:33 PM
 | 
Aug 28, 2013
 |  BC Extra  |  Company News

FDA reviewing sNDA for Boehringer's Pradaxa

FDA accepted for review an sNDA from Boehringer Ingelheim GmbH (Ingelheim, Germany) seeking to expand the use of Pradaxa dabigatran etexilate to include the acute treatment of deep vein...

Read the full 133 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$35 USD
More Info >